Regeneron Pharmaceuticals (REGN) vs Teva Pharmaceutical Industries (TEVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Teva Pharmaceutical Industries (TEVA) has outperformed Regeneron Pharmaceuticals (REGN) over the past year, gaining 95.2% versus a gain of 27.2%. Over five years, TEVA leads with a +304.8% price change compared with +34.1% for REGN. Regeneron Pharmaceuticals is the larger company by market cap ($76.40 billion vs $45.70 billion), about 1.7 times the size, while Teva Pharmaceutical Industries is growing revenue faster (+4.3% vs +1.0%).
On valuation, Regeneron Pharmaceuticals trades at a lower forward P/E (12.1x vs 12.7x for Teva Pharmaceutical Industries). Regeneron Pharmaceuticals pays a dividend yielding 0.49%, while Teva Pharmaceutical Industries does not currently pay one. Regeneron Pharmaceuticals converts more of its revenue into profit, with a net margin of 31.4% versus 8.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | REGN | TEVA |
|---|---|---|
| Share price | $742.12 | $39.18 |
| Market cap | $76.40B | $45.70B |
| 1-day change | +0.46% | +0.13% |
| YTD return | -3.85% | +25.54% |
| 1-year return | +27.24% | +95.22% |
| 5-year return | +34.14% | +304.75% |
| P/E ratio (TTM) | 18.35 | 65.30 |
| Forward P/E | 12.07 | 12.68 |
| EPS (TTM) | $40.44 | $0.60 |
| Dividend yield | 0.49% | 0.00% |
| Annual dividend | $3.64 | $0.00 |
| Revenue (latest FY) | $14.34B | $17.26B |
| Revenue growth (YoY) | +0.99% | +4.32% |
| Net income (latest FY) | $4.50B | $1.41B |
| Gross margin | — | 51.79% |
| Operating margin | 24.95% | 12.50% |
| Net margin | 31.41% | 8.17% |
| 52-week high | $859.34 | $40.79 |
| 52-week low | $541.00 | $18.83 |
| Distance from 52-week high | -13.64% | -3.95% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +15.38% | +15.62% |
| Average volume | 741.47K | 5.32M |
| Shares outstanding | 101.14M | 1.17B |
| Employees | 15,410 | 31,173 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TEVA has outperformed REGN by 68.0 percentage points over the past year.
- Teva Pharmaceutical Industries trades at a higher earnings multiple (65.3x vs 18.4x trailing P/E).
- Regeneron Pharmaceuticals is more profitable, keeping 31.4 cents of every revenue dollar as net income versus 8.2 cents for Teva Pharmaceutical Industries.
About Regeneron Pharmaceuticals
REGN stock →Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees
About Teva Pharmaceutical Industries
TEVA stock →Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Health Care · Biotechnology: Pharmaceutical Preparations · 31,173 employees
REGN vs TEVA FAQ
Which is bigger, Regeneron Pharmaceuticals or Teva Pharmaceutical Industries?
Regeneron Pharmaceuticals (REGN) is larger, with a market capitalization of $76.40B compared with $45.70B for Teva Pharmaceutical Industries (TEVA).
Which stock has performed better over the past year, REGN or TEVA?
TEVA returned +95.22% over the past 12 months, compared with +27.24% for REGN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, REGN or TEVA?
REGN has the lower trailing P/E at 18.4, versus 65.3 for TEVA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Regeneron Pharmaceuticals or Teva Pharmaceutical Industries?
Regeneron Pharmaceuticals pays a dividend yielding 0.49%, while Teva Pharmaceutical Industries does not currently pay a regular dividend.
Are Regeneron Pharmaceuticals and Teva Pharmaceutical Industries in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.